REDUCING R(I)SK IN TNBC

BioCentury.jpeg

VANCOUVER, British Columbia and SAN DIEGO, Feb. 07 2019 - Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in 80% of TNBC tumors, Phoenix aims to develop a targeted therapeutic, and has partnered with Roche on a companion diagnostic.

Read the story on BioCentury here